JP2023516925A5 - - Google Patents
Info
- Publication number
- JP2023516925A5 JP2023516925A5 JP2022550778A JP2022550778A JP2023516925A5 JP 2023516925 A5 JP2023516925 A5 JP 2023516925A5 JP 2022550778 A JP2022550778 A JP 2022550778A JP 2022550778 A JP2022550778 A JP 2022550778A JP 2023516925 A5 JP2023516925 A5 JP 2023516925A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence number
- optionally
- lcdr2
- hcdr1
- lcdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2002581.3A GB202002581D0 (en) | 2020-02-24 | 2020-02-24 | Novel antibodies |
| GB2002581.3 | 2020-02-24 | ||
| PCT/GB2021/050459 WO2021171002A1 (en) | 2020-02-24 | 2021-02-24 | Novel antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026077580A Division JP2026133459A (ja) | 2020-02-24 | 2026-05-01 | 新規の抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023516925A JP2023516925A (ja) | 2023-04-21 |
| JP2023516925A5 true JP2023516925A5 (cg-RX-API-DMAC7.html) | 2024-02-13 |
Family
ID=70108379
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550778A Pending JP2023516925A (ja) | 2020-02-24 | 2021-02-24 | 新規の抗体 |
| JP2022550813A Active JP7858536B2 (ja) | 2020-02-24 | 2021-02-24 | Ex vivoガンマデルタt細胞集団 |
| JP2026007486A Pending JP2026086466A (ja) | 2020-02-24 | 2026-01-20 | Ex vivoガンマデルタt細胞集団 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550813A Active JP7858536B2 (ja) | 2020-02-24 | 2021-02-24 | Ex vivoガンマデルタt細胞集団 |
| JP2026007486A Pending JP2026086466A (ja) | 2020-02-24 | 2026-01-20 | Ex vivoガンマデルタt細胞集団 |
Country Status (17)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202006989D0 (en) * | 2020-05-12 | 2020-06-24 | Gammadelta Therapeutics Ltd | Methods for isolating gamma delta t cells |
| KR20230160253A (ko) | 2021-02-17 | 2023-11-23 | 감마델타 테라퓨틱스 엘티디 | 항-tcr 델타 가변 1 항체 |
| MX2023009544A (es) | 2021-02-17 | 2023-11-28 | Gammadelta Therapeutics Ltd | Anticuerpos anti-variable delta 1 de tcr multiespecíficos. |
| CN119080924B (zh) * | 2024-07-04 | 2025-02-25 | 上海交通大学医学院附属第九人民医院 | 一种单克隆免疫球蛋白及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| CN100591761C (zh) | 2004-08-19 | 2010-02-24 | 加的夫大学学院咨询有限公司 | 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途 |
| CN102453701B (zh) * | 2010-10-26 | 2014-08-13 | 中国医学科学院基础医学研究所 | 基因修饰CDR3δ移植型γδT淋巴细胞及其抑癌用途 |
| CN105859889B (zh) | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| RU2756247C2 (ru) * | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| JP6799895B2 (ja) * | 2015-06-09 | 2020-12-16 | リンファクト−リンフォサイト アクティベイション テクノロジーズ エス.エー. | TCRγδ+T細胞の生産方法 |
| US10946095B2 (en) | 2015-09-02 | 2021-03-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT) |
| US10456211B2 (en) | 2015-11-04 | 2019-10-29 | Medicrea International | Methods and apparatus for spinal reconstructive surgery and measuring spinal length and intervertebral spacing, tension and rotation |
| PE20190115A1 (es) | 2016-04-15 | 2019-01-16 | Immunext Inc | Anticuerpos vista antihumanos y su uso |
| CN118421557A (zh) | 2016-05-12 | 2024-08-02 | 阿迪塞特治疗公司 | 选择性扩增γδT细胞群的方法及其组合物 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| WO2019005637A2 (en) | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF |
| WO2019147735A1 (en) | 2018-01-23 | 2019-08-01 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
| JP7457007B2 (ja) | 2018-09-19 | 2024-03-27 | ラヴァ・セラピューティクス・エヌ・ヴイ | 二重作用CD1d免疫グロブリン |
| GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| CA3127103A1 (en) | 2019-01-23 | 2020-07-30 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
| WO2020159368A1 (en) | 2019-02-01 | 2020-08-06 | Lava Therapeutics B.V. | Novel cd40-binding antibodies |
| CA3136251A1 (en) | 2019-04-08 | 2020-10-15 | Memorial Sloan Kettering Cancer Center | Cd19 antibodies and methods of using the same |
| CA3148588A1 (en) | 2019-08-16 | 2021-02-25 | GammaDelta Therapeutics Limited | Ex vivo gamma delta t cell populations |
| JP2022545196A (ja) * | 2019-08-16 | 2022-10-26 | ガンマデルタ セラピューティクス リミテッド | 抗tcrデルタ可変1抗体の治療的使用 |
| GB2586487B (en) | 2019-08-21 | 2024-03-06 | Bae Systems Plc | Materials Classifier |
| MX2023009544A (es) | 2021-02-17 | 2023-11-28 | Gammadelta Therapeutics Ltd | Anticuerpos anti-variable delta 1 de tcr multiespecíficos. |
| KR20230160253A (ko) | 2021-02-17 | 2023-11-23 | 감마델타 테라퓨틱스 엘티디 | 항-tcr 델타 가변 1 항체 |
-
2020
- 2020-02-24 GB GBGB2002581.3A patent/GB202002581D0/en not_active Ceased
-
2021
- 2021-02-24 EP EP21709757.5A patent/EP4110813A1/en active Pending
- 2021-02-24 JP JP2022550778A patent/JP2023516925A/ja active Pending
- 2021-02-24 AU AU2021228266A patent/AU2021228266A1/en active Pending
- 2021-02-24 IL IL295696A patent/IL295696A/en unknown
- 2021-02-24 MX MX2022010383A patent/MX2022010383A/es unknown
- 2021-02-24 CN CN202180028136.1A patent/CN115697401A/zh active Pending
- 2021-02-24 US US17/904,890 patent/US20230159638A1/en active Pending
- 2021-02-24 CA CA3168973A patent/CA3168973A1/en active Pending
- 2021-02-24 KR KR1020227029501A patent/KR20220164473A/ko active Pending
- 2021-02-24 PE PE2022001812A patent/PE20230438A1/es unknown
- 2021-02-24 US US17/801,786 patent/US12698328B2/en active Active
- 2021-02-24 AU AU2021225390A patent/AU2021225390A1/en active Pending
- 2021-02-24 BR BR112022016894A patent/BR112022016894A2/pt unknown
- 2021-02-24 EP EP25177102.8A patent/EP4591882A3/en active Pending
- 2021-02-24 KR KR1020227033455A patent/KR20220145894A/ko active Pending
- 2021-02-24 EP EP21709758.3A patent/EP4110387B1/en active Active
- 2021-02-24 CN CN202180030584.5A patent/CN115461369A/zh active Pending
- 2021-02-24 MX MX2022010239A patent/MX2022010239A/es unknown
- 2021-02-24 WO PCT/GB2021/050460 patent/WO2021171003A1/en not_active Ceased
- 2021-02-24 IL IL295852A patent/IL295852A/en unknown
- 2021-02-24 WO PCT/GB2021/050459 patent/WO2021171002A1/en not_active Ceased
- 2021-02-24 BR BR112022016671A patent/BR112022016671A2/pt unknown
- 2021-02-24 JP JP2022550813A patent/JP7858536B2/ja active Active
- 2021-02-24 CA CA3172340A patent/CA3172340A1/en active Pending
-
2022
- 2022-08-23 CL CL2022002296A patent/CL2022002296A1/es unknown
- 2022-08-30 ZA ZA2022/09699A patent/ZA202209699B/en unknown
- 2022-09-21 CO CONC2022/0013542A patent/CO2022013542A2/es unknown
- 2022-09-22 CO CONC2022/0013633A patent/CO2022013633A2/es unknown
- 2022-09-22 EC ECSENADI202274030A patent/ECSP22074030A/es unknown
-
2026
- 2026-01-20 JP JP2026007486A patent/JP2026086466A/ja active Pending